Aperiomics Adds Jason Zhang to Team as Software Engineer

Ashburn, VA – August 28, 2017 — Aperiomics, a biotechnology company that saves lives by harnessing the power of next-generation sequencing to identify any known pathogen (bacteria, virus, fungi or parasite) in a single test, today announced that Jian “Jason” Zhang has joined the company as a software engineer.

Jason joins the research and development division of Aperiomics with strong experience as a web developer, software project manager and software engineer. Before Aperiomics, he launched a number of major successful commercial websites and he is fluent in all of the major programming languages – Java, JavaScript, Typescript, Python, Ruby and others. He is also an expert in full-stack web development, especially in AngularJS, Angular2, Rails and Django frameworks.

“This is an exciting time for Aperiomics. Jason is the third member of the team announced since last month as we continue to grow,” said company CEO Dr. Crystal Icenhour. “We’ve built a team of highly skilled world-class technologists, making our services indispensible to the medical community and the patients they serve.”

Jason earned his M.S. degree in information technology from Virginia Polytechnic Institute and State University, and an M.A. degree in human resources management from Michigan State University.

In his spare time, Zhang is an avid athlete and sports fan. In 2004 he was among the torch runners during the 2004 Athens Olympics Games. He regularly participates in regional 5K and 10K races as well as open-water swimming competitions. Jason is training for his first triathlon later this year. He was an athlete in high school and college and won several provincial collegiate championship titles in track and field including the 110-meter hurdles. He still holds a track record at Jinan University in China.

About Aperiomics

Aperiomics is the only company identifying every bacteria, DNA virus, fungi or parasite in one test. Clinicians and patients call on Aperiomics to identify infectious diseases that other tests cannot identify. The only company of its kind and scope in the world, Aperiomics identifies every known pathogen (bacteria, virus, fungi or parasite) in a single test through next-generation sequencing of the DNA or RNA in any sample (patient, environmental, etc.). The complete genetic fingerprint of that sample is then compared to the Aperiomics Microbial Database™- the most comprehensive database of microorganisms, including the world’s largest collection of pathogens. This breakthrough is only possible through Aperiomics and can be used to identify unknown/chronic infections, limit the use of antibiotics and solve difficult medical cases. Patients and their families often contact Aperiomics directly after hearing about their successes in helping others. Aperiomics was named among Life Sciences Innovators in 2016 and a finalist in the 2017 Greater Washington Innovation Awards.